Read More

Bristol Myers’ Antitrust Allegations: Lawsuit Over Alleged Patent Deception For Blood Cancer Drug

Bristol Myers Squibb Co (NYSE: BMY) faces fresh allegations in a recent lawsuit, accused of employing deceptive patents and illicit strategies to preserve its dominant position in the blood cancer drug market with Pomalyst (pomalidomide) long after it should have faced competition from generic alternative

BMY